We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search

Clear all

Refine your search

Content type

Tags

Territory

Language

197 results found

Article

Dilworth IP | USA | 28 May 2019

Lack of Obviousness in Methods for Cancer Treatment

In Neptune Generics, LLC v. Eli Lilly & Co. the Federal Circuit upheld the Patent Trial and Appeals Board’s inter partes review decisions that

Article

Dilworth IP | USA | 9 May 2019

Are Your Secrets Still Safe? How Trade Secret Protection is Evolving Under the DTSA

Trade secret law provides protection for information that its owner takes reasonable measures to keep secret and that derives independent economic

Article

Dilworth IP | USA | 7 May 2019

Pain Treatment, Kidney Failure, and 101

In Endo Pharmaceuticals Inc. v. Teva the Federal Circuit has further clarified the patent eligibility of treatment methods which include natural

Article

Dilworth IP | USA | 9 Apr 2019

Déjà vu at the Federal Circuit: Personal Web Technologies, LLC, v. Apple, Inc.

There is a scene in the Big Lebowski where the Dude complains about the lousy day he just had as he tosses down some snacks at a bowling alley bar

Article

Dilworth IP | USA | 19 Mar 2019

Lead Compound Analysis in Mylan v. RCT

Lead compound analysis (LCA) has been used in the evaluation of chemical compound Obviousness for the past 20 years.1 This approach supplemented the

Article

Dilworth IP | USA | 12 Mar 2019

Use Your Calendar & Confidentiality to Protect the Next Big Idea

In January, the Supreme Court issued a ruling on how the commercial life of a new product can become fatal to the possibility of obtaining a patent

Article

Dilworth IP | USA | 4 Mar 2019

Determining Trademark Confusion with DuPont Factors

Forty years ago, people were dancing to Stayin Alive by the Bee Gee’s, munching on Reese’s Pieces for the first time, and watching John Travolta &

Article

Dilworth IP | USA | 7 Feb 2019

Obviousness, Prodrugs and the Rule of 5: Amerigen Pharmaceuticals Limited v. UCB Pharma GmbH

In Amerigen Pharmaceuticals Limited v. UCB Pharma GMBH, 2017-2596 (Fed. Cir. January 11, 2019), the Federal Circuit upheld the Board’s IPR finding

Article

Dilworth IP | USA | 22 Jan 2019

Rising Carbon Dioxide Levels: Capture Methods & Patent Trends

Recent data from NOAA, the National Oceanic and Atmospheric Administration, indicates that current atmospheric carbon dioxide (CO2) levels are at 409

Article

Dilworth IP | USA | 15 Jan 2019

The Final Score: 2018 Drug & Biologic Patent Approvals

The past year was a big year for FDA approved new drugs and biologics - 59 in fact, compared to 46 in 2017 and a mere 22 in 2016. From the published

Previous page 1 2 3 ...